North Chicago, United States
In 2013, AbbVie became a separate entity from Abbott Laboratories and is now a global biopharmaceutical corporation that conducts research. Its primary goal is to advance therapies that target some of the most severe and intricate diseases worldwide, utilizing its proficient employees and unconventional innovation techniques. With a team of about 29,000 staff worldwide and its subsidiary, Pharmacyclics, AbbVie delivers medicine to over 175 nations.
32
Total Investments
24
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Biotechnology, Financial Services
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About AbbVie Ventures
Recent Investments (32)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Acquisition | •••••• | Jun 2024 | |
| Seed Round | •••••• | Jan 2024 | |
| Series A | •••••• | Jun 2023 | |
| Series D | •••••• | May 2023 | |
| Unknown | •••••• | Feb 2023 | |
•••• ••••
|
Series C | •••••• | Nov 2022 |
|
•••• ••••
|
Series A | •••••• | Jan 2022 |
|
•••• ••••
|
Series A | •••••• | Nov 2021 |
|
•••• ••••
|
Series C | •••••• | Oct 2021 |
|
•••• ••••
|
Series B | •••••• | Aug 2021 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
